<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">Facilitated by the increase in opioid addiction and availability of synthetic opioids, injection drug use (IDU) associated HIV outbreaks have occurred across the globe [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Many opioids are injectable, promoting conditions that expedite the rapid transmission of communicable diseases, including HIV and hepatitis C (HCV), and exacerbating these serious public health epidemics as has been the case in the United States [
 <xref ref-type="bibr" rid="CR1">1</xref>, 
 <xref ref-type="bibr" rid="CR2">2</xref>]. Additionally, challenges in linkage to care, retention in care, and viral suppression in high risk people who inject drugs (PWID) are well documented, with estimates that less than half of PWID living with HIV in the US are virally suppressed [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR4">4</xref>]. Further, as homelessness and participation in transactional sex are typically affiliated with PWID, disease transmission is compounded among such high-risk individuals [
 <xref ref-type="bibr" rid="CR5">5</xref>, 
 <xref ref-type="bibr" rid="CR6">6</xref>].
</p>
